Why pleiotropic interventions are needed for alzheimer's disease

Molecular Neurobiology

Volumn 41, Issue 2-3, 2010, Pages 392-409

  Frautschy, Sally A ^a,b,c   Cole, Greg M ^a,b,c  

^a Veteran's Administration   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Curcumin; Inflammation; Non steroidal anti inflammatory drugs; Tau; Tau kinases; Amyloid

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENT COMPONENT C1Q; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; FLUORODEOXYGLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3BETA; IBUPROFEN; LIPOXYGENASE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; TARENFLURBIL; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); ENZYME INHIBITOR; PEPTIDE FRAGMENT;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CELL LOSS; CEREBROSPINAL FLUID; CHELATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; ENCEPHALITIS; ENERGY METABOLISM; GLUCOSE UTILIZATION; GLYCOGENOLYSIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; LONG TERM POTENTIATION; MEMORY; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; NERVE CELL; NERVE CELL MEMBRANE; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; OXIDATIVE STRESS; PATHOGENESIS; PENTOSE PHOSPHATE CYCLE; PHAGOCYTOSIS; PLEIOTROPY; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC MEMBRANE; ANIMAL; CLINICAL TRIAL (TOPIC); DOWN SYNDROME; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; CURCUMIN; DOCOSAHEXAENOIC ACIDS; DOWN SYNDROME; ENERGY METABOLISM; ENZYME INHIBITORS; HUMANS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 77955084717     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12035-010-8137-1     Document Type: Conference Paper

References (200)

1. Cole GM, Frautschy SA (2006) Commentary on "Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery." Pleiotropic approaches to Alzheimer's and other diseases of aging. Alzheimers Dement 2:284-286
2. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A (1988) Clinical, pathological and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 23:138-144
3. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45:358-368
4. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA, McKeel D, Morris JC, Hulette CM, Schmechel D, Reiman EM, Rogers J, Stephan DA (2008) Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neuro-biol Aging 31:549-566
5. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9:119-128
6. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580
7. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
8. Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L (1996) Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46:707-719
9. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185
10. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA (2009) Reexamining Alzheimer's disease: evidence for a protective role for amyloid-13 protein precursor and amyloid-|3. J Alzheimers Dis 18:447-452
11. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA (2004) Challenging the amyloid cascade hypothesis: senile plaques and amyloid-13 as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 1019:1-4
12. Ishida A, Furukawa K, Jeffrey NK, Mattson MP (1997) Secreted form of b-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. NeuroReport 8:2133-2137
13. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O (2008) Picomolar amyloid-13 positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28:14537-14545
14. Cole GM, Frautschy SA (2001) Church baptizes Joseph and Perry. Eccentric views absolved. Neurobiol Aging 22:147-150, discussion 161-1143
15. Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41:1261-1268
16. Morihara T, Chu T, Ubeda O, Beech W, Cole GM (2002) Selective inhibition of A|342 production by NSAID R-enantiomers. J Neurochem 83:1-4
17. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7:483-493
18. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557-2564
19. Schwab C, Hosokawa M, McGeer PL (2004) Transgenic mice overexpressing amyloid |3 protein are an incomplete model of Alzheimer disease. Exp Neurol 188:52-64
20. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CC, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-13 assembly in the brain impairs memory. Nature 440:352-357
21. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid |3 protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539
22. Murray CA, Lynch MA (1998) Evidence that increased hippocampal expression of the cytokine interleukin-1 (3 is a common trigger for age-and stress-induced impairments in long-term potentiation. J Neurosci 18:2974-2981
23. Hauss-Wegrzyniak B, Vannucchi MG, Wenk GL (2000) Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats. Brain Res 859:157-166
24. Hutton M, Lewis J, Dickson D, Yen SH, McGowan E (2001) Analysis of tauopathies with transgenic mice. Trends Mol Med 7:467-470
25. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25:10637-10647
26. Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A (2007) Hyper-phosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. EMBO J 26:5143-5152
27. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223
28. Kokjohn TA, Roher AE (2009) Antibody responses, amyloid-β peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 8:88-97
29. St George-Hyslop PH, Morris JC (2008) Will anti-amyloid therapies work for Alzheimer's diseasé Lancet 372:180-182
30. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259
31. Cummings JL, Cole G (2002) Alzheimer disease. JAMA 287:2335-2338
32. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM (2006) Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281:1205-1214
33. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672
34. Iqbal K, Liu F, Gong CX, Alonso AD, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuro-pathol 118:53-69
35. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E (2009) Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 48:1740-1752
36. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102:227-231
37. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95-102
38. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA (2009) GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33:193-206
39. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. Nature 382:120-121
40. Reich EE, Markesbery WR, Roberts LJ 2nd, Swift LL, Morrow JD, Montine TJ (2001) Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 158:293-297
41. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ (1997) 4-Hydroxy-2-nonenal pyrrole adducts in human neuro-degenerative disease. J Neuropathol Exp Neurol 56:866-871
42. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6:93-97
43. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid |3-protein toxicity. Cell 77:817-827
44. Behl C, Davis J, Cole GM, Schubert D (1992) Vitamin E protects nerve cells from amyloid |3-protein toxicity. Biochem Biophys Res Commun 186:944-950
45. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D (2004) Early vitamin E supplementation in young but not aged mice reduces A|3 levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18:323-325
46. Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA, Perry G (2009) Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic Res 43:156-164
47. Shinto L, Quinn J, Montine T, Baldauf-Wagner S, Oken B, Bourdette D, Kaye J (2008) Omega-3 fatty acids and lipoic acid in Alzheimer's disease. Neurology 70A393
48. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA (2001) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123:39-46
49. Liang X, Wang Q, Hand T, Wu L, Breyer RM, Montine TJ, Andreasson K (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25:10180-10187
50. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Wilson RS, Scherr PA (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287:33230-33237
51. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61:82-88
52. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E et al (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222
53. Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72:2115-2121
54. Wolf G (2007) Estimation of the human daily requirement of vitamin E by turnover kinetics of labeled RRR-alpha-tocopherol. Nutr Rev 65:46-48
55. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NE, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421
56. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA (2004) NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann N Y Acad Sci 1035:68-84
57. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM (2005) Ibuprofen suppresses interleukin-113 induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate |3-amyloid (A|3) pathology in Alzheimer's models. Neuropsychopharmacology 30:1111-1120
58. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J Neurosci 23:9796-9804
59. Heneka MT, Sastre M, Dumitrescu-Ozimek L, HankeA, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128:1442-1453
60. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT (2006) Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPAR-gamma. Proc Natl Acad Sci USA 103:443-448
61. Moore AH, Wu M, Shaftel SS, Graham KA, O'Banion MK (2009) Sustained expression of interleukin-1β in mouse hippocampus impairs spatial memory. Neuroscience 164:1484-1495
62. Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, Rudy JW, Maier SF (2009) Time course of hippocampal IL-1 β and memory consolidation impairments in aging rats following peripheral infection. Brain Behav Immun 23:46-54
63. Li Y, Liu L, Barger SW, Griffin WS (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphoryla-tion and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23:1605-1611
64. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ (2000) Complement component C1q modulates the phagocytosis of Aβ by microglia. Exp Neurol 161:127-138
65. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99:10837-10842
66. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK (2007) Sustained hippocampal IL-1 β overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117:1595-1604
67. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349-354
68. Frautschy SA, Yang F, Irizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152:307-317
69. Frautschy S, Cole GM, Baird A (1992) Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid. Am J Pathol 140:1389-1399
70. Wisniewski T, Konietzko U (2008) Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol 7:805-811
71. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D (2008) A two-year study with fibrillar β-amyloid (Aβ) immunization in aged canines: effects on cognitive function and brain Aβ. J Neurosci 28:3555-3566
72. McGeer EG, McGeer PL (2010) Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 19:355-361
73. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18:415-421
74. Webster S, Bradt B, Rogers J, Cooper N (1997) Aggregation state-dependent activation of the classical complement pathway by the amyloid b peptide. J Neurochem 69:388-398
75. Mrak RE, Griffin WS (2005) Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 8:369-375
76. Sapolsky RM (1986) Glucocorticoid toxicity in the hippocampus: reversal by supplementation with brain fuels. J Neurosci 6:2240-2244
77. Qi D, Rodrigues B (2007) Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 292:E654-E667
78. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66:300-305
79. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao Ashe K, Frautschy SA, Cole GM (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22:983-991
80. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28:639-647
81. Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70:1672-1677
82. Aisen PS (2008) The inflammatory hypothesis of Alzheimer disease: dead or alivé Alzheimer Dis Assoc Disord 22:4-5
83. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896-905
84. Laino C (2009) In follow-up analysis of clinical trial, NSAIDs seem to preserve cognitive function in patients with healthy brains. Neurol Today 9:21-22
85. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23:159-169
86. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20(15):5709-5714
87. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-7509
88. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207:225-236
89. Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM (2009) A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res 21:102-110
90. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P (2008) Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 14:1419-1427
91. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11:1311-1318
92. Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY (2008) Amyloid β peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106:45-55
93. Lin TN, Wang Q, Simonyi A, Chen JJ, Cheung WM, He YY, Xu J, Sun AY, Hsu CY, Sun GY (2004) Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain. J Neurochem 90:637-645
94. Jensen MD, Sheng W, Simonyi A, Johnson GS, Sun AY, Sun GY (2009) Involvement of oxidative pathways in cytokine-induced secretory phospholipase A2-IIA in astrocytes. Neuro-chem Int 55:362-368
95. Clerici F, Del Sole A, Chiti A, Maggiore L, Lecchi M, Pomati S, Mosconi L, Lucignani G, Mariani C (2009) Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. Q J Nucl Med Mol Imaging 53:646-657
96. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63:2332-2340
97. Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, Cotman CW (2003) Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 61:1673-1679
98. Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, Dekosky ST (1996) Alterations in functional neuroanatomical connectivity in Alzheimer's disease. Positron emission tomography of auditory verbal short-term memory. Ann N Y Acad Sci 777:239-242
99. Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST (1996) Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease. Neurology 46:692-700
100. Backman L, Andersson JL, Nyberg L, Winblad B, Nordberg A, Almkvist O (1999) Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology 52:1861-1870
101. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE (2009) Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J Neurosci 29:14770-14778
102. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM (2009) Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 326:1005-1007
103. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106:14670-14675
104. Bigl M, Bruckner MK, Arendt T, Bigl V, Eschrich K (1999) Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm 106:499-511
105. Parnetti L, Reboldi GP, Gallai V (2000) Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia. Neurology 54:735-737
106. Parnetti L, Gaiti A, Brunetti M, Avellini L, Polidori C, Cecchetti R, Palumbo B, Senin U (1995) Increased CSF pyruvate levels as a marker of impaired energy metabolism in Alzheimer's disease. J Am Geriatr Soc 43:316-318
107. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9:309-317
108. Baum L, Hansen L, Masliah E, Saitoh T (1996) Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Mol Chem Neuropathol 29:253-261
109. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 53:703-717
110. Gomez-Sintes R, Hernandez F, Bortolozzi A, Artigas F, Avila J, Zaratin P, Gotteland JP, Lucas JJ (2007) Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 26:2743-2754
111. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93:105-117
112. Mann DM, Sumpter PQ, Davies CA, Yates PO (1987) Glycogen accumulations in the cerebral cortex in Alzheimer's disease. Acta Neuropathol 73:181-184
113. Liang Z, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2007) Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem 103:2462-2470
114. Mulder C, Scheltens P, Barkhof F, Gundy C, Verstraeten RA, de Leeuw FE (2005) Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease. J Am Geriatr Soc 53:1073-1074
115. Mulder C, van der Flier WM, Veerhuis R, Bouwman F, Jakobs C, Verhoeven NM, Barkhof F, Scheltens P, Blankenstein MA (2007) Association between vitamin B6 and white matter hyperintensities in patients with Alzheimer's disease not mediat ed by homocysteine metabolism. J Am Geriatr Soc 55:956-958
116. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, Skurat AV, Delgado-Escueta AV, Minassian BA, Depaoli-Roach AA, Roach PJ (2007) Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA 104:19262-19266
117. Huang L, Hollingsworth RI, Castellani R, Zipser B (2004) Accumulation of high-molecular-weight amylose in Alzheimer's disease brains. Glycobiology 14:409-416
118. Cross AJ, Crow TJ, Johnson JA, Dawson JM, Peters TJ (1985) Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia. J Neurol Sci 71:137-143
119. Heneka MT, Galea E, Gavriluyk V, Dumitrescu-Ozimek L, Daeschner J, O'Banion MK, Weinberg G, Klockgether T, Feinstein DL (2002) Noradrenergic depletion potentiates β-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci 22:2434-2442
120. Nazarali AJ, Reynolds GP (1992) Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cell Mol Neurobiol 12:581-587
121. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Kimura H (1987) Reduced nicotinamide adenine dinucleotide phosphate diaphorase histochemistry in neocortex and hippocampus in patients with Alzheimer type dementia and aged controls. Rinsho Shinkeigaku 27:1059-1063
122. Zubenko GS, Moossy J, Claassen D, Martinez AJ, Rao GR (1990) Brain regional analysis of NADH-cytochrome C reduc-tase activity in Alzheimer's disease. J Neuropathol Exp Neurol 49:206-214
123. Jacobs RW, Farivar N, Butcher LL (1985) Alzheimer dementia and reduced nicotinamide adenine dinucleotide (NADH)-diaph-orase activity in senile plaques and the basal forebrain. Neurosci Lett 53:39-44
124. Tsuchiya A, Hardy J, Burbacher TM, Faustman EM, Marien K (2008) Fish intake guidelines: incorporating n-3 fatty acid intake and contaminant exposure in the Korean and Japanese commu nities. Am J Clin Nutr 87:1867-1875
125. Levine KE, Levine MA, Weber FX, Hu Y, Perlmutter J, Grohse PM (2005) Determination of mercury in an assortment of dietary supplements using an inexpensive combustion atomic absorption spectrometry technique. J Automat Meth Manag Chem 2005:211-216
126. Maclean C, Issa A, Newberry S, Mojica W, Morton S, Garland R, Hilton L, Traina S, Shekelle P (2005) Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases. Evid Rep Technol Assess (Summ) (114):1-88
127. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63:1545-1550
128. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633-645
129. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25:3032-3040
130. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63:1402-1408
131. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32:1538-1544
132. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A (2010) Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 6(1-10):e11
133. Cole GM, Frautschy SA (2010) DHA may prevent age-related dementia. J Nutr 140:869-874
134. Cole GM, Ma QL, Frautschy SA (2009) Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 81:213-221
135. Heller AR, Rossler S, Litz RJ, Stehr SN, Heller SC, Koch R, Koch T (2006) Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 34:972-979
136. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem NJ, Frautschy SA, G.M. C (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J NeuroSci 22:617-626
137. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, LaFerla FM (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27:4385-4395
138. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23:563-572
139. Cleland LG, Caughey GE, James MJ, Proudman SM (2006) Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J Rheumatol 33:1973-1979
140. Little SJ, Lynch MA, Manku M, Nicolaou A (2007) Docosahex-aenoic acid-induced changes in phospholipids in cortex of young and aged rats: a lipidomic analysis. Prostaglandins Leukot Essent Fatty Acids 77:155-162
141. Galarraga B, Ho M, Youssef HM, Hill A, McMahon H, Hall C, Ogston S, Nuki G, Belch JJ (2008) Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology (Oxford) 47:665-669
142. Akbar M, Calderon F, Wen Z, Kim HY (2005) Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA 102:10858-10863
143. Rao JS, Ertley RN, Lee HJ, DeMar JC Jr, Arnold JT, Rapoport SI, Bazinet RP (2007) n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 12:36-46
144. Wu A, Ying Z, Gomez-Pinilla F (2008) Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 155:751-759
145. Yavin E, Brand A, Green P (2002) Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr Neurosci 5:149-157
146. Hossain MS, Hashimoto M, Gamoh S, Masumura S (1999) Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. J Neurochem 72:1133-1138
147. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115:2774-2783
148. Innis SM (2007) Dietary (n-3) fatty acids and brain development. J Nutr 137:855-859
149. He C, Qu X, Cui L, Wang J, Kang JX (2009) Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci USA 106:11370-11375
150. Katakura M, Hashimoto M, Shahdat HM, Gamoh S, Okui T, Matsuzaki K, Shido O (2009) Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix-loop-helix transcription factors and cell cycle in neural stem cells. Neuroscience 160:651-660
151. Pifferi F, Jouin M, Alessandri JM, Haedke U, Roux F, Perriere N, Denis I, Lavialle M, Guesnet P (2007) n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. Prostaglandins Leukot Essent Fatty Acids 77:279-286
152. Tsukada H, Kakiuchi T, Fukumoto D, Nishiyama S, Koga K (2000) Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys. Brain Res 862:180-186
153. Hashimoto M, Hossain S, Shimada T, Shido O (2006) Docosahexaenoic acid-induced protective effect against impaired learning in amyloid β-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 33:934-939
154. Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML, Eskesen JG, Zuo CS, Cohen BM, Renshaw PF (2004) Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 161:1922-1924
155. Wassall SR, Stillwell W (2008) Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem Phys Lipids 153:57-63
156. Litman BJ, Niu SL, Polozova A, Mitchell DC (2001) The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: visual transduction. J Mol Neurosci 16:237-242, discussion 279-284
157. Salem N Jr, Litman B, Kim HY, Gawrisch K (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945-959
158. De Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, Perlmann T (2000) Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290:2140-2144
159. Gani OA, Sylte I (2008) Molecular recognition of docosahex-aenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. J Mol Graph Model 27:217-224
160. Calderon F, Kim HY (2007) Role of RXR in neurite outgrowth induced by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 77:227-232
161. Ma Q-L, Yang F, Rosario E, Ubeda O, Beech W, Gant D, Chen P, Hudspeth B, Chen C, Zhao Y, Vinters H, Frautschy S, Cole G (2009) Aβ oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via JNK signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29:9078-9089
162. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Tanila H, Kiliaan AJ (2007) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 28:16-29
163. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33:482-498
164. Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoot D, Nyby MD, Tuck ML, Frautschy SA, Cole GM (2007) Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J Neurosci 27:14299-14307
165. Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farkas T (2003) Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci USA 100:1580-1585
166. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24:11120-11126
167. Nourooz-Zadeh J, Liu EHC, Yhlen B, Anggard EE, Halliwell B (1999) F4-Isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 72:734-740
168. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ 2nd, Morrow JD, Montine TJ (2004) Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128:117-124
169. Cole GM, Frautschy SA (2006) Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr Health 18:249-259
170. Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007) Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1-75
171. Cole GM, Teter B, Frautschy SA (2007) Neuroprotective effects of curcumin. Adv Exp Med Biol 595:197-212
172. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370-8377
173. Cole GM, Yang F, Lim GP, Cummings JL, Masterman DL, Frautschy SA (2003) A rationale for curcuminoids for the prevention or treatment of Alzheimer's disease. Curr Med Chem Immunol Endocr Metab Agents 3:15-25
174. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901
175. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095-1104
176. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT (2006) Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-amyloid plaque imaging. J Med Chem 49:6111-6119
177. Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J, Baron GS (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 77:5499-5502
178. Brunden KR, Ballatore C, Crowe A, Smith AB 3rd, Lee VM, Trojanowski JQ (2009) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol (in press)
179. Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, DyrksT, Weggen S,MandelkowE, SchmidtB(2008) Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's diseasé Chem. Med. Chem 3:165-172
180. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM (2001) Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging 22:993-1005
181. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH (1991) Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51:813-819
182. Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, Lee MJ, Yang CS (2004) Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Car-cinogenesis 25:1671-1679
183. Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC (1996) Strategy and planning for chemopreventive drug development: clinical development plan: curcumin. J Cell Biochem Suppl 26:72-85
184. Rao CV, Rivenson A, Simi B, Reddy BS (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55:259-266
185. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST (2008) Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 56:1065-1073
186. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D (2008) 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. FASEB J 22:1169-1178
187. Chen YR, Tan TH (1998) Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17:173-178
188. Gao M, Zhou H, Li X (2009) Curcumin protects PC12 cells from corticosterone-induced cytotoxicity: possible involvement of the ERK1/2 pathway. Basic Clin Pharmacol Toxicol 104:236-240
189. Yao Y, Chinnici C, Tang H, Trojanowski JQ, Lee VM, Pratico D (2004) Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuro-inflammation 1:21
190. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25:5446-5454
191. Polydoro M, Acker CM, Duff K, Castillo PE, Davies P (2009) Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29:10741-10749
192. Tabaton M (2004) Oxidative stress and β-APP proteolytic processing. Neurobiol Aging 25(S2):S69 (S64-02-03)
193. Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6:367-377, discussion 443-1369
194. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA (2008) Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 326:196-208
195. Kang SK, Cha SH, Jeon HG (2006) Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev 15:165-174
196. Kim SJ, Son TG, Park HR, Park M, Kim MS, Kim HS, Chung HY, Mattson MP, Lee J (2008) Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J Biol Chem 283:14497-14505
197. Rao P, Knaus EE (2008) Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11:81s-110s
198. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28:110-113
199. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90:1011-1015
200. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG (2010) Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58:2095-2099